Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03467191
Other study ID # STUDY2017_00000346
Secondary ID R01AA025936
Status Active, not recruiting
Phase Early Phase 1
First received
Last updated
Start date February 13, 2018
Est. completion date July 31, 2024

Study information

Verified date February 2024
Source Carnegie Mellon University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to identify risk factors that prospectively predict alcohol problems in young adults.


Description:

The vast majority of alcohol use takes place in social settings, yet nearly all human experimental work has administered alcohol to individuals in isolation. This study will examine the effects of alcohol in social groups and test whether these responses predict the escalation of alcohol use and development of alcohol use disorder symptoms. Participants will also complete smartphone surveys querying subjective responses to alcohol in their daily lives. N=400 male and female young adults will participate in a laboratory session with two other participants and will consume either a moderate dose of alcohol or placebo beverage. Subjective and objective responses to alcohol will be assessed. Participants will also complete surveys on their smartphones; these will occur during drinking episodes and at random times throughout the day. Follow-up sessions will occur at 6-months and 12-months, to collect information about drinking habits and potential alcohol-related problems.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 782
Est. completion date July 31, 2024
Est. primary completion date July 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 29 Years
Eligibility Inclusion Criteria: - 21 to 29 years of age - currently drinks alcohol - owns a smartphone Exclusion Criteria: [Exclusion criteria are masked from public viewing until data collection is complete. Please contact project managers.]

Study Design


Intervention

Drug:
Alcohol
target BAC .08%
Other:
Placebo
placebo beverage

Locations

Country Name City State
United States Carnegie Mellon University Pittsburgh Pennsylvania

Sponsors (4)

Lead Sponsor Collaborator
Carnegie Mellon University National Institute on Alcohol Abuse and Alcoholism (NIAAA), Penn State University, University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Alcohol Use at 12-months Timeline Follow Back Method 12-month follow-up
Primary Change from Baseline Alcohol Use Disorder Symptoms at 12-months Structured Clinical Interview for DSM-5 12-month follow-up
Secondary Subjective Responses to Alcohol Participants will indicate how they feel after drinking alcohol using the Brief-Biphasic Alcohol Effects Scale, which is a 6-item scale assessing alcohol's acute stimulant and sedative effects (0-10 scale, with higher scores indicating higher values). 1 day (laboratory session) and 21-day ambulatory assessment period
Secondary Social Bonding Facial expressions of emotions using Paul Ekman's Facial Action Coding System (FACS). The duration of AUs associated with positive and negative affect will be coded. 1 day (laboratory session)
Secondary Social Bonding Perceived Group Reinforcement Scale, which is a 12-item scale assessing self-reported bonding (1-9 scale, with higher scores indicating more bonding). 1 day (laboratory session)
Secondary Mood 8-item Mood Measure, which is an 8-item scale assessing mood items from each of the four quadrants of the affective circumplex (with higher scores indicating more felt emotion). 1 day (laboratory session)
Secondary Alcohol Use Quantity of standard drinks consumed. 21-day ambulatory assessment period
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A
Completed NCT02511886 - A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder Phase 2
Active, not recruiting NCT02185131 - Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD. Phase 2